Welcome to our dedicated page for Solid Bioscience news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Bioscience stock.
Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences Inc. (Nasdaq: SLDB) has announced a change to its 2020 Annual Meeting of Stockholders, which will now be held virtually on June 16, 2020, at 8:00 a.m. Eastern Time due to COVID-19 restrictions. Shareholders who held shares by April 20, 2020, are entitled to participate and vote. Access to the meeting requires a control number from proxy materials. The company emphasizes that all stockholders should vote in advance, and technical support details are provided in a filed proxy supplement.
Solid Biosciences (Nasdaq: SLDB) announced that its IGNITE DMD Phase I/II clinical trial remains on clinical hold by the FDA. In response to the hold, the company submitted a revised clinical protocol in April 2020, focusing on patient safety and manufacturing process improvements. However, the FDA requested further data, which Solid expects to submit by Q3 2020. SGT-001, their gene therapy candidate for Duchenne muscular dystrophy, aims to deliver a synthetic dystrophin gene and has received designations intended to expedite the drug's development.